{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T04:03:40Z","timestamp":1784347420904,"version":"3.55.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7791-26","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:10:48Z","timestamp":1784326248000},"source":"Crossref","is-referenced-by-count":0,"title":["ALT Reduction Following Pemafibrate Treatment in MASLD and MetALD with Dyslipidemia: Associations with the Baseline Liver Enzyme Levels"],"prefix":"10.2169","author":[{"given":"Takako","family":"Nomura","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, HITO Medical Center, Japan"},{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, HITO Medical Center, Japan"},{"name":"Division of Innovative Medicine for Hepatobiliary and Pancreatology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoyuki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, HITO Medical Center, Japan"},{"name":"Division of Innovative Medicine for Hepatobiliary and Pancreatology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, HITO Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, HITO Medical Center, Japan"},{"name":"Division of Innovative Medicine for Hepatobiliary and Pancreatology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Ayaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, HITO Medical Center, Japan"},{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Ogi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, HITO Medical Center, Japan"},{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Ogi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, HITO Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, HITO Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78: 1966-1986, 2023.","DOI":"10.1097\/HEP.0000000000000520"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79: 1542-1556, 2023.","DOI":"10.1097\/HEP.0000000000000696"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 29: 101133, 2024.","DOI":"10.1016\/j.aohep.2024.101485"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARalpha modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis 249: 36-43, 2016.","DOI":"10.1016\/j.atherosclerosis.2016.02.029"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Honda Y, Kessoku T, Ogawa Y, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep 7: 42477, 2017.","DOI":"10.1038\/srep42477"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hassan M, Al-Obaidi H, Karrick M, et al. Effect of pemafibrate on the lipid profile, liver function, and liver fibrosis among patients with metabolic dysfunction-associated steatotic liver disease. Gastroenterol Res 17: 159-174, 2024.","DOI":"10.14740\/gr1750"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Ichikawa T, Oba H, Owada M, et al. Evaluation of the effects of pemafibrate on metabolic dysfunction-associated steatotic liver disease with hypertriglyceridemia using magnetic resonance elastography combined with fibrosis-4 index and the magnetic resonance imaging-aspartate aminotransferase score. JGH Open 7: 959-965, 2023.","DOI":"10.1002\/jgh3.13012"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ishibashi S, Arai H, Yokote K, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol 12: 173-184, 2018.","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64: 73-84, 2016.","DOI":"10.1002\/hep.28431"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bush K, Kivlihan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT Alcohol Consumption Questions (AUDIT-C): An Effective Brief Screening Test for Problem Drinking. Arch Intern Med 158: 1789-1795, 1998.","DOI":"10.1001\/archinte.158.16.1789"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Williams B, Mancia G, Spiering W, et al. Practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH\/ESC task force for the management of arterial hypertension: erratum. J Hypertens 37: 456, 2019.","DOI":"10.1097\/HJH.0000000000002026"},{"key":"12","unstructured":"12. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41: 255-323, 2020."},{"key":"13","unstructured":"13. Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J 41: 111-188, 2020."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 47: 586-595, 2012.","DOI":"10.1007\/s00535-012-0533-z"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Takahashi H, Ono M, Hyogo H, et al. Biphasic effect of alcohol intake on the development of fatty liver disease. J Gastroenterol 50: 1114-1123, 2015.","DOI":"10.1007\/s00535-015-1058-z"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"17","doi-asserted-by":"crossref","first-page":"e13057","DOI":"10.1002\/jgh3.13057","volume":"8","author":"H Ono","year":"2024","unstructured":"17. Ono H, Atsukawa M, Tsubota A, et al. Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: a single-arm prospective study. JGH Open 8: e13057, 2024.","journal-title":"JGH Open","ISSN":"https:\/\/id.crossref.org\/issn\/2397-9070","issn-type":"print"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Iwasa M, Sugimoto R, Eguchi A, et al. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: The influence of alcohol consumption. Eur J Gastroenterol Hepatol 36: 793-801, 2024.","DOI":"10.1097\/MEG.0000000000002766"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Sugimoto R, Iwasa M, Eguchi A, et al. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. Front Med (Lausanne) 10: 1073025, 2023.","DOI":"10.3389\/fmed.2023.1073025"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Morishita A, Oura K, Takuma K, et al. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int 17: 606-614, 2023.","DOI":"10.1007\/s12072-022-10453-1"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Hatanaka T, Kosone T, Saito N, et al. Effect of 48-week pemafibrate on nonalcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score. JGH Open 5: 1183-1189, 2021.","DOI":"10.1002\/jgh3.12650"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7791-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:25:46Z","timestamp":1784345146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7791-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":21,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7791-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7791-26"}}